Audit: QRS - Devil’s Claw for Health & Longevity
Audit conducted on 12/09/2026 03:06 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER: at-a-glance vs ER Conclusion; action/time cells vs ER Therapeutic Protocol, Practical Considerations, Discontinuation & Cycling; benefits/risks vs the ER tier headings; all 10 markers, targets, why-strings and the cadence sentence vs the ER Monitoring Protocol & Defining Success table and paragraph. No unsupported claim found. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Hedged ER wording is carried through: “results are mixed” (at-a-glance) mirrors the ER Conclusion’s “genuinely mixed”; “no long-term safety data exist” mirrors “no long-term safety data at all”; “no trial has tested once-daily administration” (action_2_sub) is verbatim ER. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening detected. Pregnancy remains an absolute contraindication (“Pregnancy in any trimester, and breastfeeding”), matching the ER’s avoid-list rather than being downgraded to a caution. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Categories are preserved. The antiarrhythmic/chronotropic/inotropic entry sits under Contraindications because the ER states it is “treated as an absolute contraindication in drug references” (ER line 311); no Benefit- or Risk-Modifying Factor is surfaced as a gate item. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers, author names, brand names (Doloteffin, Harpadol, Rosaxan) or trial citations appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind are introduced; action_3_sub refers only to “the dose-ranging low-back-pain trial” without naming or citing it, as the ER does. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Tone matches the ER’s measured, evidence-weighted register throughout. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert and data-driven (harpagoside milligrams, biomarker ranges, cycle windows) while remaining accessible and actionable. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents thresholds and evidence tiers; no directive second-person instruction anywhere. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No clinical advice phrasing; the only prescriptive sentence is the fixed template disclaimer in the footer. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Cells state what the evidence shows (“All supporting trials used two or three divided doses”) rather than recommending. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No occurrence of “you”, “your”, “we”, “our” or “us” anywhere in the document body. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language throughout; the technical terms that remain (NYHA Class III–IV, Child-Pugh Class C, eGFR, P-glycoprotein) are load-bearing decision-gate thresholds that items 8.5/9.5 require to be preserved. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every gate, benefit and risk item is a single compact phrase with rationale, mechanism and citations stripped. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no direct address to the reader. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Content is pitched at a proactive, risk-aware audience: harpagoside-standardised dosing, a 10-marker monitoring panel and a cycling schedule. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Assumes willingness to dose three times daily with meals for 12–16 weeks and to run repeat bloodwork — inconvenient protocols presented without hedging on adherence. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not written for the general population; the monitoring panel and cycle discipline presuppose deliberate self-experimentation. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Weighting reflects the audience: the at-a-glance leads with where the evidence is strongest, and the absence of long-term safety data is surfaced up front. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not appear; framing is longevity-oriented via the fixed header. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Formal register maintained. The lede uses “taken orally as a bitter extract” rather than “taken by mouth”; no “pill”, “shot” or “bad reaction”. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | Diff against [qrs_template] confirms all card headings (Protocol, Time to effect, Benefits, Risk & Side Effects, Monitoring, Qualitative Assessment), both gate headings, all four tier labels and the Marker/Target/Why column headers are byte-identical to the template. |
| 3.2 | All “<span data-qrs-var=”NAME”>…</span>” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 named template spans are present; the repeatable marker_#name/target/why and qualitative_item# placeholders are correctly expanded to marker_1–10 and qualitative_item_1–6. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Diff against the template shows changes confined to spans a checklist item addresses; the , and elements and all CSS are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section is empty — every section the QRS draws on (Protocol, Expected Benefits, Potential Risks & Side Effects, Key Interactions & Contraindications, Monitoring) is populated, so no empty-state phrasing is required. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | ER bold labels are reused verbatim: “Standard daily dose”, “Single versus split dosing” and “Flare dose” (ER Therapeutic Protocol), “Time to effect” (ER Practical Considerations) and “Practical cycle pattern” (ER Discontinuation & Cycling). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No label is paraphrased, abbreviated or invented; time_2_label “Maximal effect” is ER wording verbatim (“reference sources put maximal effect at one to four months”, ER line 425). |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No 🟩, 🟥, 🟨 or ⚠️ characters appear; the ER’s “⚠️ Conflicted” markers on two benefit and one risk heading were correctly stripped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to the minimum the completeness items (8.2, 9.2, 14.2, 15.2) permit: gate items carry no rationale, benefit and risk items are single phrases, and marker targets are trimmed (e.g. the WOMAC row reduced from 24 words in the ER to 9). |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | The metadata comment opens on line 2, immediately after <!doctype html>, and precedes every other comment, head and body element. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | YAML opens with “—” on line 3 and closes with “—” on line 13; the preceding text “QRS — Metadata (invisible, parsed by audit tooling)” sits outside the block. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment and not echoed by any visible element. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed; only duration: “00:03” is quoted, which YAML requires because the value contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: devils_claw_2026-0912-0009_Opus_ER.md — matches the source ER on disk. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.9.11 — matches the version badge at the top of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0912-0257 — correct YYYY-MMDD-HHMM form. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5 |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version number with no additional qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: devils_claw_2026-0912-0009_Opus_QRS.html — matches the actual filename. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine frontmatter keys: no stray whitespace and no unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | header_topic is “Devil’s Claw for Health & Longevity”, matching the ER canonical_topic with entity encoding. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | header_subline_date is 09/12/2026, the correct MM/DD/YYYY rendering of qrs_creation_date 2026-0912-0257. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | header_subline_model is “Opus 5”, matching qrs_creator_ai_fullname. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header carries only the title and the template subline; no badge, version stamp, alternate-names line, audit date or variant marker was added. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Distils the ER Conclusion: what the intervention is, where the evidence holds (short courses in low back pain), where it does not (hip and knee osteoarthritis), and the tolerability trade-off. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 47 words — within the 60-word ceiling. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause traces to a distinct ER Conclusion passage: the description to line 501, the low-back-pain and osteoarthritis readings to line 503, and the indigestion/diarrhoea and missing long-term data to line 505. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms or specialist classifications; “indigestion”, “diarrhoea” and “osteoarthritis” are terms a non-specialist uses unprompted. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes or p-values. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect sizes, relative risks or statistical results. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine entries derive from the ER Key Interactions & Contraindications section — eight from its “Populations who should avoid Devil’s Claw” list and one from the antiarrhythmic bullet the ER calls an absolute contraindication. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Complete: all eight ER avoid-list populations are present, none dropped, plus the drug class the ER designates an absolute contraindication. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | All nine entries are discrete <li></li> elements inside the [stop_items] span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Rationale and glosses are stripped throughout — e.g. the ER’s “given documented uterus-contracting activity” and “for whom no safety data exist” are removed, and no item carries a trailing dash clause. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every decision-relevant qualifier survives: “within 12 months”, “≥160/100 mmHg untreated”, “NYHA Class III–IV”, “Child-Pugh Class C”, “below 30 mL/min/1.73 m²”, “under 18”. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its contraindication list; the only symbols present are numeric thresholds (≥160/100 mmHg), not severity orderings. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is populated, which is correct — the ER names eight populations that should avoid the intervention. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!– empty: ER names no population that should avoid the intervention –> | N/A | The section is not empty, so no explanatory HTML comment is required. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eleven entries derive from the twelve bullets of the ER Key Interactions & Contraindications section. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All twelve ER interaction bullets are accounted for: eleven appear here and the antiarrhythmic bullet is correctly excluded because it is carried as a Contraindication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | All eleven entries are discrete <li></li> elements inside the [caution_items] span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Consequences and mitigations are stripped — e.g. the ER’s “weekly international normalised ratio checks for four weeks” and “four-hour dose separation and drug-level monitoring” do not appear; no trailing dash clauses remain. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every named-drug parenthetical is preserved; two are trimmed to fit the one-page budget (dipyridamole from the antiplatelet list, naproxen from the NSAID list) but none is dropped entirely. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its interactions list; all parentheticals are plain comma-separated drug or supplement examples. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is populated, which is correct — the ER names twelve interactions that change how the intervention is used. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!– empty: ER names no interaction that changes how the intervention is used –> | N/A | The section is not empty, so no explanatory HTML comment is required. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three action sets derive from the ER Therapeutic Protocol section (lines 364, 368, 378). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Standard daily dose, split dosing schedule and flare dose are the three decision-critical implementation aspects; the remaining ER bullets (competing approaches, who popularised each, pharmacogenetics, sex, age) are contextual rather than actionable. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Therapeutic Protocol section contains far more than three actionable aspects, so no set is left unused. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action fields carry substantive ER-derived content; no placeholder text remains. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Onset (from 4 weeks), maximal effect (1 to 4 months) and the practical cycle pattern with its four-week reassessment window are the ER’s three time-anchored findings. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered from earliest observable response through maximal effect to the cycle/reassessment window, tracking the low-back-pain and osteoarthritis benefits the ER ranks highest. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects exist in the ER, so no set is left unused. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time fields carry substantive ER-derived content; no placeholder text remains. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information (ER lines 425, 403), so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All eleven benefit entries map one-to-one onto the headings of the ER Expected Benefits section. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four tier spans are present and populated. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items are reduced to the ER heading text alone; the ER’s Magnitude: lines (e.g. “WOMAC pain fell 23.8%”) and mechanistic sentences are absent. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheticals survive; the ER’s inline glosses such as “(Western Ontario and McMaster Universities osteoarthritis index…)” are stripped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers (high, medium, low, speculative) carry items in the ER, so no span needed hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All eleven risk entries map one-to-one onto the headings of the ER Potential Risks & Side Effects section. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four tier spans are present and populated. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items are reduced to the ER heading text alone; the ER’s incidence figures (“about 3% of patients”, “8.1% versus 26.7%”) and case-report detail are absent. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheticals survive; the ER’s glosses such as “(indigestion with upper-abdominal discomfort)” and “(low blood sodium, causing confusion and weakness)” are stripped. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers (high, medium, low, speculative) carry items in the ER, so no span needed hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | The table reproduces the ER Monitoring Protocol & Defining Success biomarker table, and the cadence line reproduces its closing paragraph. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All ten rows of the ER biomarker table are present in ER order: haemoglobin, ferritin, serum sodium, blood pressure, alanine aminotransferase, eGFR, fasting glucose, high-sensitivity C-reactive protein, serum uric acid and the WOMAC/VAS pain score, each with its ER target value. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Populated verbatim from the ER: blood pressure twice weekly for four weeks then monthly, sodium and full blood count at 4 and 12 weeks, and the remaining panel at 12 weeks. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | The six items reproduce the qualitative-marker list closing the ER Monitoring Protocol & Defining Success section (ER lines 470–475). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers are present verbatim: morning stiffness duration, pain-free walking distance, weekly rescue-analgesic count, sleep continuity, willingness to load the joint, and upper-abdominal comfort after each dose. |
Issues 12/09/2026 03:06
Pass rate 100.00%. No issues found.
Issues 12/09/2026 03:03
- 2.15 — Colloquial phrase in protocol cell: [time_2_sub] (line 519) reads “it acts over weeks rather than on a bad day”; “a bad day” is consumer-grade phrasing in the QRS’s own voice, where the ER’s own bullet label supplies the formal term “acute pain relief” (ER 429).
Fixes 12/09/2026 03:03
- 2.15 — Colloquial phrase replaced with clinical term: [time_2_sub] changed from “it acts over weeks rather than on a bad day” to “it acts over weeks and does not deliver acute pain relief on demand”, adopting the ER’s own formal term “acute pain relief” (ER 429).